Drastic price cut will weaken Korea’s R&D capability

Published: 2011-10-12 06:59:00

Updated: 2011-10-12 06:59:00

The Korea Pharmaceutical Manufacturers Association said Monday that a drastic price cut would make domestic drug producers unable to invest in research and development (R&D), which is persuasive, given that they cannot invest much in R&D when they had the resources.

The KPMA said it will wipe out profits, stifle R&D and open the door for foreign dominance of the sector, claiming it will unde...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.